Companies · Other Health Care

Emvenio Research, Inc.

SPARKS · Other Health Care

Diligence memoA one-page analyst read on Emvenio Research, Inc. — recommendation, valuation, rhythm, risks.
$9.2M
Total raised · real
1
Rounds
0.5×
Latest step-up
Top 27%
Sector rank · raised
Series A
Latest stage · inferred · Thu Aug 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Emvenio Research, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.39× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.
Dormant
  • Last raise 3.9 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Emvenio Research, Inc. is one of 5376 Other Health Care companies tracked from SPARKS. By capital raised it ranks in the upper tier (ahead of 74% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
8
Investors (latest)
2022
Year incorporated
2022-08-04
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeries A · 2022-08-04 Raised $9.2M (real) Modeled valuation $87M (est)$9.2M$87MSeries A2022Series A · 2022-08-04 Raised $4.5M (real) Modeled valuation $43M (est)$4.5M$43MSeries A2022+$4.5MCumulative $14M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$9.2M · 2022
Series A extension$4.5M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$87.4M
Base estimate est.
$11.8M
Conservative case
$293.4M
Upside case
$41.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $87.4M · 2022-08-042022Series A · modeled $42.9M · 2022-08-042022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
3.9 yr
Elapsed time used
3.9 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
3.9 yr
On record since
2022
First round
2
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.8× above median
This company$9.2M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.8× of median
This company$4.5M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 4.0× above median
This company$87.4M
Sector median$22.1M

Raised more than 74% of sector peers (real $). Modeled value above 76% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #20 of 196.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)CareHarmony, Inc. · Series A Raised $17.4M · modeled $145.1M (est)Dragonfly Endoscopy Inc. · Series A Raised $12.7M · modeled $141.8M (est)NuvoAir Holdings, Inc. · Series A Raised $10.7M · modeled $124.9M (est)Post Acute Recovery, Inc. · Series A Raised $14.5M · modeled $122.9M (est)Micro Interventional Devices, Inc. · Series A Raised $14.0M · modeled $118.9M (est)Etiometry Inc. · Series A Raised $15.6M · modeled $114.6M (est)SafKan, Inc. · Series A Raised $13.0M · modeled $108.4M (est)BehaVR Holdings, Inc. · Series A Raised $12.1M · modeled $102.0M (est)Outliers Inc. · Series A Raised $13.6M · modeled $101.6M (est)RevMedica, Inc. · Series A Raised $14.2M · modeled $101.1M (est)Innovoyce LLC · Series A Raised $9.9M · modeled $97.5M (est)Prixz, Inc. · Series A Raised $9.2M · modeled $97.3M (est)Emvenio Research, Inc. (this company) Raised $9.2M · modeled $87.4M (est)Emvenio Research, Inc.
CompanyStageRaised · realValue · estvs peer med.
CareHarmony, Inc.Series A$17.4M$145.1M3.96×
Dragonfly Endoscopy Inc.Series A$12.7M$141.8M3.87×
NuvoAir Holdings, Inc.Series A$10.7M$124.9M3.41×
Post Acute Recovery, Inc.Series A$14.5M$122.9M3.35×
Micro Interventional Devices, Inc.Series A$14.0M$118.9M3.25×
Etiometry Inc.Series A$15.6M$114.6M3.13×
SafKan, Inc.Series A$13.0M$108.4M2.96×
BehaVR Holdings, Inc.Series A$12.1M$102.0M2.78×
Outliers Inc.Series A$13.6M$101.6M2.77×
RevMedica, Inc.Series A$14.2M$101.1M2.76×
Innovoyce LLCSeries A$9.9M$97.5M2.66×
Prixz, Inc.Series A$9.2M$97.3M2.66×
Emvenio Research, Inc. this companySeries A$9.2M$87.4M2.39×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$9.2M2022-08-04$41.7M$87.4M90%
Series A$4.5M2022-08-04$20.4M$42.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$9.2M2022-08-04
    • First recorded raise — entered as Series A.
    • 23 investors on this round.
  2. Series A$4.5M2022-08-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 8 investors on this round.
Intelligence
Modeled next raise
$4.5M
Modeled next size est.range $4.5M$7.2M
0.5×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Daniel Castillo1 other2022-08
Alan Henthorne2022-08
David Shackelton2022-08
Monty Waugh2022-08
Thaddeus Wolfram2022-08
Registry & provenance

Emvenio Research, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1943068
SEC CIK
2022
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
WiserCare, Inc.Other Health CareSeed$7.5M$8.1Mnetwork1 shared operator · same sector
Prixz, Inc.Other Health CareSeries A$9.2M$97.3Msame sector · same stage
Iris Plans, Inc.Other Health CareSeries A$9.1M$75.7Msame sector · same stage
Regional Diagnostic Laboratories, Inc.Other Health CareSeries A$9.1M$91.6Msame sector · same stage
iHeart, LLCOther Health CareSeries A$9.3M$87.0Msame sector · same stage
SimpleTherapy, Inc.Other Health CareSeries A$9.0M$94.7Msame sector · same stage
Viatar CTC Solutions Inc.Other Health CareSeries A$9.0M$84.7Msame sector · same stage
Maya MD Inc.Other Health CareSeries A$9.0M$84.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Empirican Group Inc.Other Health CareSeries A$15.9M87%
EmpowrU, Inc.Other Health CarePre-Seed$15.4M85%
EmOpti, Inc.Other Health CarePre-Seed$4.1M85%
Neuro-Vascular Research & Design CorpOther Health CarePre-Seed$435K84%
Empoweru Inc.Other Health CarePre-Seed$6.5M84%
EmTheraPro, Inc.Other Health CareSeed$19.2M84%
Emano Metrics Inc.Other Health CarePre-Seed$7.7M83%
Empericus, LLCOther Health CarePre-Seed$23.1M83%
Frequently asked
How much funding has Emvenio Research, Inc. raised?
Emvenio Research, Inc. has raised approximately $9.2M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Emvenio Research, Inc.'s estimated valuation?
Provath's modeled valuation for Emvenio Research, Inc. is approximately $87.4M (modeled range $11.8M–$293.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Emvenio Research, Inc. at?
Emvenio Research, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Aug 04.
What does Emvenio Research, Inc. do and where is it based?
Emvenio Research, Inc. operates in the Other Health Care sector, based in SPARKS.
Explore related

See where Emvenio Research, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Emvenio Research, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.